NORTHWOOD, Ohio--(BUSINESS WIRE)--For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But of course the need exists, even if proper devices may not.
The Philadelphia Pediatric Medical Device Consortium (PPDC) has been formed to address this very concern. The PPDC brings engineers, biomedical researchers and clinicians from industry and academia to address the shortage of medical devices designed for children. The Children’s Hospital of Philadelphia (CHOP) received a five-year grant from the U.S. Food and Drug Administration (FDA) to form the PPDC and is one of seven pediatric device consortia nationwide recently funded by the FDA.
To assist with this important initiative of bringing pediatric medical devices to market, NAMSA is supporting the PPDC with their regulatory, quality, testing, and clinical expertise across the medical device development spectrum. To ensure communication between all parties Seth J. Goldenberg, Ph.D., a Principal Medical Research Scientist at NAMSA, is serving as the Entrepreneur-In-Residence (EIR) at the PPDC. With this personnel appointment Dr. Goldenberg and NAMSA can offer "get-to-market" strategies, networking, mentoring and coaching to the innovators at the PPDC and bring in NAMSAs global network of 750 associates as needed to support these efforts.
Together NAMSA and the PPDC hope to achieve success in accelerating pediatric medical devices into the market place for patients in need.
NAMSA (www.namsa.com) is a global medical device research organization providing a comprehensive range of services to prove efficacy, preclinical and clinical safety of medical devices, IVDs, HCT/P and combination products. For more than 45 years, NAMSA clients have utilized its testing and consulting services to bring safe and effective therapies to market.